Metabolic distortion reveals early markers of disease
At a biomedical research center in Spain's Basque Country, scientists have built a clock that measures not the years a person has lived, but the pace at which their body is aging — a distinction that may prove more meaningful than any birthday. By reading the molecular language of blood through NMR metabolomics and machine learning, the team at CIC bioGUNE has created a tool that can surface early disease signals years before symptoms appear, challenging medicine's long reliance on chronological age as a proxy for health. The gap between who we are on paper and who we are at the cellular level, it turns out, is where illness quietly begins.
- Standard clinical tests routinely miss early disease markers that are already written into the molecular composition of a person's blood — a silence this technology is designed to break.
- Patients with fatty liver disease registered as biologically more than 14 years older than their actual age, while prostate cancer patients skewed nearly 5 years older, revealing how dramatically disease can accelerate the body's internal clock.
- The same single blood sample can estimate over 25 clinical parameters — from inflammation to kidney function — compressing what once required multiple tests into one non-invasive draw.
- The research team, drawing on data from more than 20,000 individuals, is now pushing toward validation across broader healthcare systems, the critical threshold between promising science and clinical reality.
- If adopted widely, the metabolic clock could shift medicine's posture from reactive to anticipatory — catching the body's distress signal before it becomes a diagnosis.
Researchers at CIC bioGUNE in Spain's Basque Country have developed a metabolic aging clock that reads the molecular signature of blood to calculate biological age — a number that often diverges sharply from the one on a birth certificate. Led by Prof. José M. Mato and Dr. Óscar Millet, the team used NMR metabolomics combined with machine learning, drawing on blood samples from more than 20,000 people, primarily through the AKRIBEA cohort conducted in collaboration with the Mondragón Corporation. Their findings were published in npj Metabolic Health and Disease.
The clock's significance becomes clear when applied to people with existing conditions. Men with prostate cancer showed a metabolic age nearly five years beyond their chronological age. In patients with fatty liver disease, the gap exceeded 14 years — and crucially, these distortions appeared before symptoms emerged, offering a window for early intervention. The researchers also found that distinct subtypes of fatty liver disease produced different aging patterns, nuances that conventional blood work typically cannot detect.
Dr. Millet describes the core ambition plainly: to obtain a measure of age that is independent of what a passport says, one that reveals when molecular biology is outpacing the calendar. Beyond aging itself, the same blood sample can estimate more than 25 standard clinical parameters — inflammation, kidney function, and others — from a single non-invasive test, suggesting that blood serum already carries far more health information than medicine currently reads.
The team is now working toward validation across different healthcare systems and populations, the step that would allow the metabolic clock to move from research into clinical practice — and potentially shift medicine's focus from treating disease after it arrives to identifying the people most at risk before it does.
Imagine a blood test that could tell you not how many years you've lived, but how fast your body is actually aging. Researchers at CIC bioGUNE, a biomedical research center in Spain's Basque Country, have built exactly that: a metabolic aging clock that reads the molecular signature of your blood and translates it into a measure of biological age—one that often diverges sharply from the number on your birth certificate.
The tool works by analyzing small molecules in blood samples using a technique called NMR metabolomics, then feeding that data through machine learning algorithms to calculate what the scientists call your "metabolic age." The difference between this number and your actual age can reveal something crucial: early warning signs of disease that standard clinical tests would miss entirely. The research, published in npj Metabolic Health and Disease, was developed by a team led by Prof. José M. Mato and Dr. Óscar Millet, drawing on blood samples from more than 20,000 people across a wide age range, primarily from the AKRIBEA cohort, a large health study conducted in collaboration with the Mondragón Corporation.
The power of the clock becomes apparent when you look at what it found in people with existing diseases. Men with prostate cancer showed a metabolic age nearly five years older than their chronological age. But the gap widened dramatically in patients with fatty liver disease, where the metabolic clock registered them as more than 14 years older than they actually were. What makes this significant is not just the number itself, but what it signals: these metabolic distortions appear before symptoms emerge, offering doctors a chance to intervene early. The researchers also discovered that different subtypes of fatty liver disease produced distinct aging patterns—variations that conventional blood work typically fails to capture.
Dr. Millet frames the innovation in straightforward terms: the goal was to obtain a measure of age independent of what a passport says, one that could reveal when someone's molecular biology is aging faster than the calendar suggests. That divergence, he explains, is where disease markers hide. The clock doesn't just measure biological age, either. The same blood sample can be analyzed to estimate more than 25 standard clinical parameters—inflammation levels, kidney function, and others—all from a single non-invasive test. The researchers note that an enormous amount of health information is already encoded within the molecular composition of blood serum; their innovation is learning to read it more completely.
The work represents part of a broader push toward precision medicine, where treatment and prevention are tailored to individual biology rather than population averages. If the metabolic clock can be validated across different healthcare systems and populations, it could transform how doctors approach disease prevention. Rather than waiting for symptoms to appear, physicians might use this test to identify people whose metabolic age is accelerating—a signal to investigate further, to intervene earlier, to help people live not just longer but healthier. The team is now working toward that validation, hoping to expand the platform's use across clinical practice.
Notable Quotes
The importance of this study lies in the fact that discrepancies between chronological age and metabolic age may reveal early markers of disease.— Dr. Óscar Millet, head of Precision Medicine and Metabolism Laboratory
The Hearth Conversation Another angle on the story
Why does it matter that someone's metabolic age differs from their actual age? Isn't that just a number?
It's not the number itself—it's what the number is telling you. If your body is aging faster than time is passing, something is going wrong at the molecular level. That's often where disease starts, before you feel sick.
So you're saying this test catches disease before symptoms show up?
Exactly. In fatty liver disease, patients were showing metabolic ages 14 years older than they actually were. Standard blood tests might not flag that. This one does.
How does the test actually work? What's it measuring?
It analyzes the small molecules floating in your blood—metabolites—using a technique called NMR. Then machine learning finds patterns in those molecules that correlate with aging and disease. It's reading your blood's molecular signature.
And it can do all this from a single sample?
One sample. It estimates over 25 clinical parameters from the same test. Inflammation, kidney function, all of it. The information was always there in the blood; we just didn't know how to extract it.
What happens next? Is this going into hospitals soon?
Not yet. They need to validate it across different healthcare systems and populations. But if that works, yes—this could become a routine screening tool.